Our Company
Kiora Pharmaceuticals is a late-stage retinal therapeutics company committed to advancing novel treatments for patients facing vision-threatening diseases.
KIO-401 • Entering Phase 3
CRAO Is An Ocular Stroke
Central Retinal Artery Occlusion (CRAO)
A novel oral small molecule designed to protect retinal cells following acute ischemic injury.
Blood flow stops
Central retinal artery becomes occluded
Retina becomes ischemic
Starved of oxygen and nutrients
Irreversible vision loss begins
Millions of retinal cells die within minutes
Time is critical
The opportunity to save vision narrows rapidly
KIO-401 · CRAO
A Major Therapeutic Gap
There are no approved therapies for CRAO, and visual outcomes remain poor for many patients. Kiora is changing that trajectory with a differentiated small-molecule therapy designed to protect retinal tissue when every minute counts.
Our Pipeline
Multiple Pathways. One Mission.
Kiora is building a retinal therapeutics pipeline leveraging differentiated biology, with one goal: to protect sight, restore possibility and address some of the most significant unmet needs in ophthalmology.
Differentiated Science
We target distinct biological pathways that drive vision loss, pursuing novel approaches where conventional therapies fall short.
Small-Molecule Innovation
Our expertise in small molecules enables targeted therapeutic strategies designed to address complex retinal disease biology.
Addressing Critical Need
We focus on vision-threatening retinal diseases with limited or no approved treatment options and where patient need remains significant.
Building Platform Potential
Our programs have the potential to address additional indications across broader retinal diseases, such as non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma, and beyond ophthalmology.
